Another Checkpoint Inhibitor Misses Mark in Ovarian Cancer No OS or PFS benefit with nivolumab versus chemotherapy for platinum-resistant disease Sep 24, 2021
Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancer Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed Sep 17, 2021
Third Dose a Charm in Israel? Door-to-Door 'Goons'; Cervids Catch COVID, Too! A daily roundup of news on COVID-19 and the rest of medicine Jul 30, 2021
COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
Ovarian Cancer Screening Trial Still Sees No Death Reduction Researchers "disappointed" by long-term results of U.K. study of 200,000 postmenopausal women May 22, 2021
Report: Worst Hospitals for Unnecessary Procedures Lown Institute says report is the first to name hospitals with high rates of overuse May 04, 2021
Triage System Gets High Marks for Ovarian Cancer Debulking Surgery Key factors predicted threefold higher risk of 90-day mortality with primary surgery Mar 26, 2021
HIPEC Combo Doubles PFS in Advanced Ovarian Cancer Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study Mar 26, 2021
Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer Ixabepilone plus bevacizumab yielded responses in a third of patients Mar 26, 2021
Androgen Receptor Inhibitor Active in Endometrial Cancer SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer Mar 22, 2021
Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer Responses in 37% of patients with AVB-500, higher without prior bevacizumab Mar 21, 2021
Is MIS Viable for Interval Debulking in Ovarian Cancer? Retrospective study compared approach versus open surgery after neoadjuvant chemotherapy Mar 21, 2021
PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer Modest improvement in PFS with rucaparib but worse outcome for reversion mutation Mar 20, 2021
New Targeted Therapies Show Promise in Cancer Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
Kardashian Makeup Artist Hrush Achemyan's Ovarian Cancer Beauty influencer reveals diagnosis Jan 21, 2021
PARP Inhibitors Linked With Blood Cancer Risk Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden Dec 28, 2020
Immunotherapy Falls Short Again in Ovarian Cancer No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab Sep 23, 2020
Which Women Choose Hormones for Surgical Menopause? Understanding patterns of use can help improve targeting for education and counseling, researchers say Aug 12, 2020
Second Surgery Gets OS Win in Recurrent Ovarian Cancer Survival improved by nearly 8 months with cytoreductive surgery at first relapse Jun 02, 2020
Avelumab Flops Again in Ovarian Cancer Another negative phase III trial, now in the first-line setting May 19, 2020
PARP Inhibitors Still Work in HRD-Low Ovarian Cancer In VELIA, homologous recombination deficiency score prognostic but not predictive May 14, 2020
KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancers Nearly 7-month PFS boost in patients with KRAS mutations May 11, 2020
New Standard in Recurrent, Platinum-Sensitive Ovarian Cancer Pegylated liposomal doxorubicin unseats gemcitabine in standard platinum regimen Apr 21, 2020
Breastfeeding Tied to Lower Ovarian Cancer Risk Lower incidence of borderline tumors as well Apr 02, 2020
Post-Op HPV Vaccine Cuts Cervical Precancer Recurrences Plus osteoporosis in gynecologic cancer survivors, and a novel approach to CIN2/3 Mar 31, 2020
DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
After Five Months in a Coma, Young Nurse Wakes Up Chicago RN with rare autoimmune encephalitis responds to unusual treatment Jan 10, 2020
Trametinib Tx Shows Promise in Tough-to-Treat LGSOC Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer Sep 30, 2019
Data Support 'Best Drug First' in EGFR-Mutant NSCLC Six-month survival gain with osimertinib, adding to PFS, safety advantages Sep 29, 2019
PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Ca? PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines Sep 29, 2019
First-Line Combo Boosts PFS in Advanced Ovarian Ca Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup Sep 28, 2019
Obamacare Cut Racial Disparities in Cancer Care Time to cancer treatment evens in blacks and whites with Medicaid expansion Jun 03, 2019
Birth Control Pills Tied to Reduced Risk of Deadly Ovarian Ca Every 5 years of use linked with 32% reduction in risk of dying within 12 months of diagnosis Apr 04, 2019 video
Early Data Send Strong Signal in Advanced Gyn Cancers Clinical benefit rate tops 90% in pair of single-center studies Mar 19, 2019
'End of the Road' for Trabectedin in Ovarian Cancer? Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations Mar 19, 2019
When PARP Inhibitors Fail in Ovarian Cancer Study identifies subgroup for whom another go could be worthwhile Mar 18, 2019
Avelumab Combo Falls Short in Advanced Ovarian Ca But showed promise in PD-L1-positive group Mar 18, 2019
PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Ca Analysis attempts to quantify patients' quality of survival Mar 17, 2019
Lymphadenectomy Often Useless in Ovarian Cancer No survival benefit with normal nodes after complete macroscopic resection Mar 01, 2019
Does Johnson's Baby Powder Cause Cancer? Milton Packer says the $4.69-billion verdict is about anger, not medicine Jan 09, 2019
